Circulating oxidized low-density lipoproteins and arterial elasticity: comparison between men with metabolic syndrome and physically active counterparts by Pohjantähti-Maaroos, Hanna et al.
ORIGINAL INVESTIGATION Open Access
Circulating oxidized low-density lipoproteins and
arterial elasticity: comparison between men with
metabolic syndrome and physically active
counterparts
Hanna Pohjantähti-Maaroos
1,2,3*, Ari Palomäki
1,2, Päivi Kankkunen
1, Ruth Laitinen
2, Sari Husgafvel
1, Kalevi Oksanen
1
Abstract
Background: Accumulation of oxidized low-density lipoproteins in the intimae of arteries and endothelial
dysfunction are key events in the development of atherosclerosis. Patients with metabolic syndrome are at high
risk for cardiovascular diseases but the linkage between metabolic syndrome and atherosclerosis is incompletely
understood. We studied whether the levels of oxidized LDL and arterial elasticity differ between metabolic
syndrome patients and physically active controls.
Methods: 40 men with metabolic syndrome and 40 physically active controls participated in this cross-sectional
study. None of the study subjects had been diagnosed with cardiovascular disease. Levels of oxidized LDL were
assessed by a two-site ELISA immunoassay. Arterial elasticity was assessed non-invasively by the HDI/PulseWave™
CR-2000 arterial tonometer.
Results: Levels of oxidized LDL were 89.6 ± 33.1 U/L for metabolic syndrome subjects and 68.5 ± 23.6 U/L for
controls (p = 0.007). The difference remained significant after adjustment for LDL cholesterol. Large artery elasticity
index (C1) was 16.2 ± 4.1 mL/mmHgx10 for metabolic syndrome subjects and 19.4 ± 3.7 mL/mmHgx10 for
controls (p = 0.001), small artery indices (C2) were 7.0 ± 3.2 mL/mmHgx100 and 6.5 ± 2.9 mL/mmHgx100 (NS),
respectively.
Conclusions: Subjects with metabolic syndrome had elevated levels of oxidized LDL and reduced large arterial
elasticity compared to controls. This finding may partly explain the increased risk for cardiovascular diseases among
metabolic syndrome patients.
Trial registration: ClinicalTrials.gov NCT01114763
Background
Metabolic syndrome (MetS) is an accumulation of cardi-
ovascular risk factors: visceral obesity, hypertension, dys-
lipidemia and abnormal glucose tolerance or diabetes.
Subjects with metabolic syndrome are at high risk for
cardiovascular diseases [1,2]. Mechanisms that link
metabolic syndrome to increased risk are, however,
incompletely understood.
The key event in atherogenesis is oxidation of LDL
particles entrapped in the intimae of arteries [3]. Ele-
vated levels of oxidized LDL (oxLDL) have been
reported to correlate with subclinical atherosclerosis and
predict future cardiovascular events [4,5].
Oxidized LDL, together with risk factors known to
enhance atherosclerosis, damages the endothelium of the
arterial wall [3]. Dysfunction of the endothelium leads
into impaired elasticity of the artery already at an early
stage of the atherosclerotic process [6]. Aortic stiffness
has been found to predict future coronary events and
cardiovascular death in previous studies [7,8]. Especially
a reduction in the elasticity of small arteries has been
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serve as a marker for early stages of atherosclerosis [6,9].
As a part of Hämeenlinna Metabolic Syndrome
Research Program, we studied whether the levels of oxi-
dized LDL and arterial elasticity assessed by a non-inva-
sive radial artery tonometer differ between subjects with
metabolic syndrome and their physically active controls.
To our knowledge, this is the first time that both the
levels of oxLDL and arterial elasticity are reported
among the same metabolic syndrome subjects.
Methods
Subjects
40 Finnish men with metabolic syndrome diagnosed in
routine health examination and laboratory tests, and
their 40 age-matched, physically active controls were
enrolled in the study. Only men aged 30-65 were
included. Subjects with previously diagnosed cardiovas-
cular disease and subjects on cholesterol-lowering medi-
cation, ACE-inhibitor or angiotensin-receptor blocker
medication were excluded.
Metabolic syndrome was defined according to the
National Cholesterol Education Program (NCEP) as the
presence of at least three of the following five criteria
[10]:
- waist circumference > 102 cm
- serum triglycerides level ≥ 1.7 mmol/L
- serum high density lipoprotein (HDL) cholesterol
level < 1.03 mmol/L
- blood pressure ≥ 130/85 mmHg
- plasma glucose level ≥ 6.1 mmol/L or diabetes
mellitus
Information on subjects’ diseases, medication, smoking
habits, alcohol consumption and cardiovascular diseases
in family was gathered during a standardized interview.
Subjects filled in a questionnaire on their average
amount, type and mode of physical exercise per week.
We calculated the energy expenditure of mean daily
physical exercise in kilocalories by multiplying the MET
value and exercise times per week and mean duration of
exercise in hours and person’s weight in kilograms and
finally dividing it by 7 [11]. The compendium of physi-
cal activities and subjects’ self-rated intensity levels of
the exercise sessions were used in estimating the correct
MET value [12]. To exclude controls with obstructive
cardiovascular disease, participation was accepted if a
subject exercised physically more than three times a
week and more than 30 minutes per exercise without
any symptoms of cardiovascular disease. Mean alcohol
intake (g/day) was calculated by multiplying the average
number of alcohol portions/month by ethanol content
of each taken beverage and dividing it by 30. Subjects’
weight, height and waist circumference were measured.
Subjects were given both oral and written information
on the study before they signed an informed consent.
The study was approved by the ethics committee of the
Kanta-Häme Hospital District in Finland.
Laboratory Procedures
Serum levels of total cholesterol, low density lipoprotein
(LDL) cholesterol, HDL cholesterol and triglyceride
levels were analyzed by a commercial Cobas Integra
procedure (Roche). HbA1C was assessed by a standar-
dized method in % and then calculated to mmol/mol
according to Nathan et al [13]. Plasma levels of oxidized
LDL were determined as duplicates according to a vali-
dated, commercial two-site immunoassay (ELISA, Mer-
codia). The assay has been reported to have an excellent
reproducibility [14] and it uses the same monoclonal
antibody mAb-4E6 as the assays previously described by
Holvoet et al [15].
Determination of Arterial Elasticity
Arterial elasticity was measured after at least 10 minutes
of rest in a semi-sitting position. Subjects refrained from
eating, smoking, drinking caffeinated drinks and taking
medication for 12 hours and drinking alcohol for two
days prior to the measurement. Arterial elasticity was
assessed non-invasively by recording radial artery pulse
wave by an arterial tonometer (HDI/PulseWave™ CR-
2000) which uses a modified Windkessel method [9].
The capacitive elasticity of large arteries (C1) and the
reflective elasticity of small arteries (C2) were automati-
cally assessed by the CR-2000 as a mean of five most
similar pulse waves appearing during the measurement.
C1 identifies the elastic properties of aorta and other
large arteries, C2 the endothelial function of the micro-
vascular circulation [6]. Four measurements were per-
formed to gain mean large and small arterial elasticity
for every subject. Blood pressure was assessed automati-
cally by the CR-2000 during the elasticity measurement.
Statistical Methods
Statistics were analyzed with SPSS for Windows 17.0.
Differences in continuous variables between metabolic
syndrome subjects and controls were studied by Stu-
dent’s T-test in case of normality and by Mann Whitney
U-test in case of non-normality. ANOVA was used to
analyze the difference in levels of oxidized LDL between
the groups after adjustment for LDL and total choles-
terol as well as the differences in oxLDL and arterial
elasticity after adjustment for the amount of physical
activity. Differences in categorical values were calculated
by c
2 test. Data are expressed as mean ± SD. A prob-
ability value < 0.05 was considered statistically
significant.
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The clinical characteristics of the groups are reported in
Table 1 and the number of subjects with separate vari-
ables of metabolic syndrome defined by NCEP in Table
2. Clinical chemistry is presented in Table 3. Three
MetS variables were found in thirteen (32.5%), four vari-
ables in twenty-three (57.5%) and five variables in four
(10.0%) MetS subjects. Five MetS subjects and one con-
trol used beta-blockers, one subject and two controls
used aspirin, one subject and one control used calcium
channel blockers, and one subject and none of controls
used diuretics. Eight subjects and none of controls were
on diabetes medication.
Oxidized LDL levels were significantly higher among
subjects with MetS than among controls, 89.6 ± 33.1 U/
L and 68.5 ± 23.6 U/L (p = 0.007), respectively (Figure
1). The difference remained significant even after adjust-
ment for LDL cholesterol (p = 0.014) and for physical
activity (p = 0.015).
Large arterial elasticity was significantly better among
controls but there was no difference in small arterial
elasticity between the groups. Large artery elasticity
index (C1) was 16.3 ± 4.1 mL/mmHgx10 for subjects
with metabolic syndrome and 19.4 ± 3.7 mL/mmHgx10
for controls (p = 0.001). The difference remained signifi-
cant after adjustment for physical activity (p = 0.021).
Small artery indices (C2) for the metabolic syndrome
and control groups were 7.0 ± 3.2 mL/mmHgx100 and
6.7 ± 3.0 mL/mmHgx100, respectively, (NS), (Figure 2).
Discussion
Oxidized LDL levels were significantly higher and large
arterial elasticity lower among men with metabolic
Table 1 Clinical characteristics
Metabolic
Syndrome
(n = 40)
Controls
(n = 40)
p
value
Age, years 49.8 ± 7.1 50.8 ± 8.1 NS
Family history of, n (%)
- coronary heart disease 16 (40.0%) 18 (45.0%) NS
- cerebrovascular disease 8 (20.0%) 6 (15.0%) NS
Diabetics, n (%) 16 (40.0%) 1 (2.5%) <
0.001
Diagnosed with hypertension,
n (%)
9 (22.5%) 2 (5.0%) 0.048
Smoking 0.001
- current, n (%) 12 (30.0%) 1 (2.5%)
- former, n (%) 16 (40.0%) 12 (30.0%)
- never, n (%) 12 (30.0%) 27 (67.5%)
No of pack-years in smokers 16.1 ± 13.9 8.1 ± 8.3 0.030
Physical activity, kcal/day 233.8 ± 236.4 531.8 ±
274.3
<
0.001
Alcohol intake, g/day 16.9 ± 18.2 8.1 ± 6.1 0.006
BMI, kg/m
2 31.5 ± 4.7 24.0 ± 1.7 <
0.001
Waist circumference, cm 112.2 ± 12.0 87.8 ± 6.4 <
0.001
Systolic blood pressure,
mmHg
139.6 ± 15.8 127.6 ± 9.3 <
0.001
Diastolic blood pressure,
mmHg
82.1 ± 9.0 74.3 ± 7.2 <
0.001
Clinical characteristics of metabolic syndrome subjects and controls. Data are
presented as mean ± SD if not mentioned otherwise.
Table 2 Number of subjects with different MetS variables
Metabolic
Syndrome
(n = 40)
Controls
(n = 40)
Waist circumference > 102 cm, n (%) 36 (90.0%) 1 (2.5%)
Blood pressure ≥ 130/85, n (%) 40 (100.0%) 12
(30.0%)
HDL cholesterol < 1.03 mmol/L, n (%) 15 (37.5%) 1 (2.5%)
Triglycerides ≥ 1.7 mmol/L, n (%) 36 (90.0%) 2 (5.0%)
Glucose ≥ 6.1 mmol/L or diabetes, n
(%)
26 (65.0%) 5 (12.5%)
Number of metabolic syndrome subjects and controls who fulfilled separate
variables of metabolic syndrome defined by NCEP [10].
Table 3 Laboratory characteristics
Metabolic Syndrome
(n = 40)
Controls
(n = 40)
p value
Total cholesterol, mmol/L 5.98 ± 1.0 5.31 ± 0.8 0.001
HDL cholesterol, mmol/L 1.17 ± 0.2 1.68 ± 0.4 < 0.001
LDL cholesterol, mmol/L 3.87 ± 1.0 3.42 ± 0.7 0.020
Triglycerides, mmol/L 2.67 ± 1.5 0.88 ± 0.4 < 0.001
Fasting glucose, mmol/L 6.99 ± 1.8 5.53 ± 0.6 < 0.001
HbA1C, < 0.001
% 6.18 ± 0.9 5.56 ± 0.2
mmol/mol 44.1 ± 9.8 37.3 ± 2.2
Laboratory characteristics of subjects with metabolic syndrome and controls.
Data are presented as mean ± SD.
p = 0.007
Figure 1 Oxidized LDL. Levels of oxidized LDL (U/L) among
metabolic syndrome subjects and controls.
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findings on increased oxLDL among MetS have previously
been published [16-20]. However, in these previous studies
MetS definitions or laboratory techniques were different
from the ones in the present study. In addition, subjects in
the previous studies differed in age, gender or race from
the subjects participating in this study.
Our finding disagrees with a previous study by Sjogren
et al [21]. They studied 289 subjects of whom 22 had
metabolic syndrome. They found no increase in oxLDL
levels among MetS subjects compared to a control
group of healthy individuals and those with one to two
metabolic syndrome factors. A possible reason for differ-
ent results might be the small number and percentage
of MetS subjects in their study.
In our study, subjects with metabolic syndrome were
more often smokers, less active physically, and they
used more alcohol than controls. Smoking and alcohol
consumption have been reported to relate to elevated
oxLDL levels, whereas physical activity, for its part, may
improve the resistance of LDL against oxidative modifi-
cation [22-24]. Although these factors may partly contri-
bute to the increased level of oxLDL among MetS
subjects, it is noteworthy that the difference in oxLDL
remained significant after adjustment for the amount of
physical activity.
Elevated levels of oxLDL among MetS subjects may
reflect the increased systemic oxidative stress that Han-
sel et al [25] previously found to associate with meta-
bolic syndrome. Oxidative stress is believed to be
substantial in the development of atherosclerosis [26].
The association between elevated levels of oxidized LDL
and early development of atherosclerosis has previously
been reported [4]. OxLDL also seems to correlate with
established coronary heart disease, acute coronary syn-
drome and atherosclerotic plaque growth [4,5,14,15].
Induced phagocytosis of oxLDL after in vitro stimula-
tion with glucose and insulin has been reported by Sari-
gianni et al [27]. Since subjects with metabolic
syndrome often have elevated levels of glucose and insu-
lin, it may contribute to the progression of atherosclero-
sis among them. Holvoet et al reported a strong
association between circulating oxLDL, metabolic syn-
drome and increased risk for myocardial infarction [19].
Increased oxLDL among MetS subjects may thus partly
explain the connection between metabolic syndrome
and increased risk for cardiovascular events. Assessment
of oxLDL might be beneficial in risk stratification
among patients with metabolic syndrome.
Previous studies implicate that the link between ele-
vated levels of oxidized LDL and metabolic syndrome
might be the increased number of small LDL particles
more prone to oxidation [20,28]. We did not assess the
number of small dense LDL, which was a limitation of
this study.
In a study among type 2 diabetics, MetS per se was
not associated with a reduction in aortic distensibility
[29]. We found significantly lower large arterial elasticity
among Finnish metabolic syndrome patients than
among their physically active controls. In the present
study only minority of the subjects had diabetes. In
addition, we assessed small and large arterial elasticity
by a radial artery pulse wave analysis, which has been
thought to provide a more complete understanding of
arterial stiffness [30].
The established and widely used measure of regional
a r t e r i a ls t i f f n e s s ,p u l s ew a v ev e l o c i t y ,m a yb ei n a c c u r a t e
among subjects with metabolic syndrome, abdominal
obesity and diabetes [31].
There are only two previous reports on impaired large
arterial elasticity among metabolic syndrome subjects
assessed by the same pulse wave analysis as in the pre-
sent study [32,33]. Because of genetic differences, the
results reported among Chinese MetS subjects cannot
be generalized to Caucasians [32]. In the other study,
impaired large arterial elasticity was found among Cau-
casian MetS subjects [33]. However, in that study all
features of metabolic syndrome were not evaluated since
glucose and lipid profiles were not obtained.
Kals et al [34] found reduced elasticity in both small
and large arteries and increased oxidative stress among
patients with peripheral arterial disease. A study by
Morishita et al [35] demonstrated higher oxidized lipo-
protein(a) concentrations among patients with coronary
heart disease. Lipoprotein(a) concentrations also corre-
lated with pulse wave velocity among hypertensive
patients with coronary heart disease and controls. A
study by Moreau et al [36] implicated that oxidative
stress might be the reason for reduced carotid arterial
compliance among sedentary postmenopausal women.
p = 0.001
NS
Figure 2 Arterial elasticity. Large (C1, mL/mmHgx10) and small
(C2, mL/mmHgx100) arterial elasticity among metabolic syndrome
subjects and controls.
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between decreased compliance of ascending aorta and
increased levels of a marker for oxidized LDL in other-
wise healthy men and in men with borderline hyperten-
sion. Our findings are in line with these previous studies
since we report for the first time both the elevated levels
of oxLDL and decreased large arterial elasticity among
same controlled metabolic syndrome subjects.
Subclinical carotid atherosclerosis is associated with
metabolic syndrome [38]. Reduction in the elasticity of
large arteries, on its part, has been reported to relate to
atherosclerosis, future coronary events and cardiovascu-
lar mortality [7,39,40]. Reduced large arterial elasticity
found among metabolic syndrome subjects may thereby
enlighten the connection between metabolic syndrome
and the increased cardiovascular risk.
A significant cardiovascular disease may be present
among sedentary subjects although not clinically mani-
fested because of lack of physical activity. We wanted to
ensure that controls did not have obstructive athero-
sclerotic disease, like coronary heart disease or periph-
eral arterial disease. Therefore, participation of controls
was accepted if they exercised physically more than
three times a week and more than 30 minutes per
exercise.
Regular physical exercise is believed to attenuate age-
related reduction in large arterial elasticity [41]. In con-
trast, some previous reports have assessed a greater
reduction in central arterial compliance in resistance-
trained men compared with sedentary men [42,43]. In
these studies, subjects exercised regularly at a vigorous
level, as earlier studies have mainly concentrated on
subjects who exercised endurance sports at low-inten-
sity. In our study, the control group consisted of men
who regularly exercised endurance sports more than
three times a week and some even every day. Despite
the strenuous level of exercise among most of the con-
trols, their mean large arterial elasticity was much better
than among MetS patients. In a previous study, physical
activity did not predict arterial stiffness [44]. In the pre-
sent study, impairment of large arterial elasticity was
evident among MetS subjects even after adjustment for
physical activity. Therefore, we believe that the amount
of exercise as an inclusion criterion of controls would
have revealed a manifest cardiovascular disease without
interfering with the results.
We found no difference in small arterial elasticity
between metabolic syndrome subjects and controls. In
line with this finding, metabolic syndrome has pre-
viously been reported to selectively impair central pulse
wave velocity but not peripheral pulse wave velocity
[45]. Small arterial elasticity is often reduced in the pre-
sence of hypertension, diabetes and smoking [9,46,47].
In the present study, all these conditions were more
often present among metabolic syndrome subjects. Sta-
tins, ACE-inhibitor and angiotensin-receptor blocker
medications are known to improve endothelial function
and thus small arterial elasticity [48-50]. However, sub-
jects with these medications were excluded from the
present study. Whether regular physical exercise
damages the endothelium in microvasculature and
explains the reduction in small arterial elasticity among
physically active subjects has not been published.
Conclusions
Both the elevated levels of oxidized LDL and reduction
in large arterial elasticity were found among men with
metabolic syndrome when compared to their physically
active controls. Our finding may enlighten the connec-
tion between increased cardiovascular risk and meta-
bolic syndrome.
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